UK's Smith+Nephew CFO John Rogers to step down for external role

• Rogers' departure comes weeks after Smith+Nephew cut its annual revenue growth outlook due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing
• Pierre Palassian, who joined Smith+Nephew in 2017 and previously held senior roles at AbbVie and Abbott Laboratories, will serve as interim CFO
• Smith+Nephew shares gained nearly 14% during Rogers' tenure, and he will receive no severance payment upon departure

Summary

Smith+Nephew announced that CFO John Rogers will step down at the end of September 2024 after approximately two-and-a-half years with the UK-based medical products company. Rogers, who assumed the CFO role in early 2024, is leaving to pursue an external opportunity in the United States.

Key Developments:

• Interim Appointment: Senior Vice President Finance and Group Controller Pierre Palassian will serve as interim CFO until a permanent replacement is named. Palassian joined Smith+Nephew in 2017 and previously held senior positions at AbbVie and Abbott Laboratories.

• Recent Performance Challenges: The departure follows Smith+Nephew's recent decision to reduce its annual revenue growth forecast after second-quarter sales missed expectations. The shortfall was attributed to weak U.S. demand for knee and hip implants and pricing pressures on skin substitutes.

• Financial Terms: Rogers will receive no severance payment, with outstanding incentive arrangements to be handled per existing terms.

• Stock Performance: Despite recent challenges, Smith+Nephew shares gained nearly 14% during Rogers' tenure as CFO.

Market Implications:

The CFO departure amid downgraded revenue guidance signals potential operational challenges for Smith+Nephew, particularly in its core U.S. orthopedic implant business. The leadership transition during a period of financial underperformance may create uncertainty for investors. However, the appointment of an experienced internal candidate as interim CFO suggests continuity in financial management. Investors should monitor upcoming quarters for stabilization in U.S. implant demand and the company's ability to execute its turnaround strategy under new financial leadership.